In last trading session, Akebia Therapeutics Inc (NASDAQ:AKBA) saw 3.19 million shares changing hands with its beta currently measuring 0.92. Company’s recent per share price level of $1.93 trading at $0.02 or 1.05% at ring of the bell on the day assigns it a market valuation of $504.17M. That closing price of AKBA’s stock is at a discount of -49.74% from its 52-week high price of $2.89 and is indicating a premium of 58.55% from its 52-week low price of $0.80. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.98 million shares which gives us an average trading volume of 3.53 million if we extend that period to 3-months.

For Akebia Therapeutics Inc (AKBA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.05 in the current quarter.

Akebia Therapeutics Inc (NASDAQ:AKBA) trade information

Upright in the green during last session for gaining 1.05%, in the last five days AKBA remained trading in the green while hitting it’s week-highest on Tuesday, 04/01/25 when the stock touched $1.93 price level, adding 3.02% to its value on the day. Akebia Therapeutics Inc’s shares saw a change of 1.58% in year-to-date performance and have moved 0.52% in past 5-day. Akebia Therapeutics Inc (NASDAQ:AKBA) showed a performance of 7.22% in past 30-days. Number of shares sold short was 16.57 million shares which calculate 5.03 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 6.5 to the stock, which implies a rise of 70.31% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -210.88% in reaching the projected high whereas dropping to the targeted low would mean a loss of -210.88% for stock’s current value.

Akebia Therapeutics Inc (AKBA) estimates and forecasts

This year revenue growth is estimated to rise 20.10% from the last financial year’s standing.

4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 44.88M for the same. And 4 analysts are in estimates of company making revenue of 44.63M in the next quarter. Company posted 32.61M and 43.65M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 32.58% during past 5 years.

Akebia Therapeutics Inc (NASDAQ:AKBA)’s Major holders

Insiders are in possession of 4.21% of company’s total shares while institution are holding 27.33 percent of that, with stock having share float percentage of 28.53%. Investors also watch the number of corporate investors in a company very closely, which is 27.33% institutions for Akebia Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at AKBA for having 11.64 million shares of worth $11.87 million. And as of 2024-06-30, it was holding 5.5499 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 9.28 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.526 of outstanding shares, having a total worth of $9.46 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 5.95 shares of worth $11.47 million or 2.52% of the total outstanding shares. The later fund manager was in possession of 5.43 shares on Feb 28, 2025 , making its stake of worth around $10.49 million in the company or a holder of 2.30% of company’s stock.